Virus-Like Particles Assembled Using Respiratory Syncytial Virus Matrix Protein Elicit Protective Immunity in Mice

References

• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58–83. doi:10.1016/j.vaccine.2012.10.083
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Gomes AC, Cabral-Miranda G, et al. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J Control Release. 2017;251:92–100. doi:10.1016/j.jconrel.2017.02.031
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–796. doi:10.1038/nri2868
   PubMed Web of Science ®Google Scholar
• Chu KB, Quan FS. Virus-like particle vaccines against respiratory viruses and protozoan parasites. Curr Top Microbiol Immunol. 2021. doi:10.1007/82_2021_232
   PubMed Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. doi:10.1016/s0140-6736(17)30938-8
   PubMed Web of Science ®Google Scholar
• Tseng HF, Sy LS, Ackerson B, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222(8):1298–1310. doi:10.1093/infdis/jiaa361
   PubMed Web of Science ®Google Scholar
• Pilie P, Werbel WA, Riddell J, Shu X, Schaubel D, Gregg KS. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis. 2015;17(4):551–557. doi:10.1111/tid.12409
   PubMed Web of Science ®Google Scholar
• McGinnes LW, Gravel KA, Finberg RW, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol. 2011;85(1):366–377. doi:10.1128/jvi.01861-10
   PubMed Web of Science ®Google Scholar
• Lee S, Quan FS, Kwon Y, et al. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res. 2014;111:129–135. doi:10.1016/j.antiviral.2014.09.005
   PubMed Web of Science ®Google Scholar
• Murawski MR, McGinnes LW, Finberg RW, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2010;84(2):1110–1123. doi:10.1128/jvi.01709-09
   PubMed Web of Science ®Google Scholar
• Lee S-H, Chu K-B, Kim M-J, et al. Virus-like particle vaccine expressing the respiratory syncytial virus pre-fusion and G proteins confers protection against RSV challenge infection. Pharmaceutics. 2023;15(3):782. doi:10.3390/pharmaceutics15030782
   PubMed Web of Science ®Google Scholar
• Shaikh FY, Cox RG, Lifland AW, et al. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles. mBio. 2012;3(1). doi:10.1128/mBio.00270-11
   PubMed Web of Science ®Google Scholar
• Meshram CD, Baviskar PS, Ognibene CM, Oomens AGP, García-Sastre A. The respiratory syncytial virus phosphoprotein, matrix protein, and fusion protein carboxy-terminal domain drive efficient filamentous virus-like particle formation. J Virol. 2016;90(23):10612–10628. doi:10.1128/jvi.01193-16
   PubMed Web of Science ®Google Scholar
• Ghildyal R, Li D, Peroulis I, et al. Interaction between the respiratory syncytial virus G glycoprotein cytoplasmic domain and the matrix protein. J Gen Virol. 2005;86(Pt 7):1879–1884. doi:10.1099/vir.0.80829-0
   PubMedGoogle Scholar
• Bajorek M, Galloux M, Richard CA, et al. Tetramerization of phosphoprotein is essential for respiratory syncytial virus budding while its N terminal region mediates direct interactions with the matrix protein. J Virol. 2021;95(7). doi:10.1128/jvi.02217-20
   PubMed Web of Science ®Google Scholar
• Walpita P, Johns LM, Tandon R, Moore ML. Mammalian cell-derived respiratory syncytial virus-like particles protect the lower as well as the upper respiratory tract. PLoS One. 2015;10(7):e0130755. doi:10.1371/journal.pone.0130755
   PubMed Web of Science ®Google Scholar
• Jiao YY, Fu YH, Yan YF, et al. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Antiviral Res. 2017;144:57–69. doi:10.1016/j.antiviral.2017.05.005
   PubMed Web of Science ®Google Scholar
• Kim KS, Kim AR, Piao Y, Lee JH, Quan FS. A rapid, simple, and accurate plaque assay for human respiratory syncytial virus (HRSV). J Immunol Methods. 2017;446:15–20. doi:10.1016/j.jim.2017.03.020
   PubMed Web of Science ®Google Scholar
• Chu KB, Lee SH, Kim MJ, Kim AR, Moon EK, Quan FS. Virus-like particles coexpressing the PreF and Gt antigens of respiratory syncytial virus confer protection in mice. Nanomedicine. 2022;17(17):1159–1171. doi:10.2217/nnm-2022-0082
   PubMed Web of Science ®Google Scholar
• Kim KH, Li Z, Bhatnagar N, et al. Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle. PLoS Pathog. 2022;18(8):e1010755. doi:10.1371/journal.ppat.1010755
   PubMedGoogle Scholar
• Kim AR, Lee DH, Lee SH, Rubino I, Choi HJ, Quan FS. Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein. PLoS One. 2018;13(1):e0191277. doi:10.1371/journal.pone.0191277
   PubMed Web of Science ®Google Scholar
• Sung RY, Hui SH, Wong CK, Lam CW, Yin J. A comparison of cytokine responses in respiratory syncytial virus and influenza A infections in infants. Eur J Pediatr. 2001;160(2):117–122. doi:10.1007/s004310000676
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, et al. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. Eur Cytokine Netw. 2007;18(3):162–167. doi:10.1684/ecn.2007.0096
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee YT, Hwang HS, et al. Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells. J Virol. 2015;89(22):11692–11705. doi:10.1128/jvi.02018-15
   PubMed Web of Science ®Google Scholar
• Démoulins T, Brügger M, Zumkehr B, et al. The specific features of the developing T cell compartment of the neonatal lung are a determinant of respiratory syncytial virus immunopathogenesis. PLoS Pathog. 2021;17(4):e1009529. doi:10.1371/journal.ppat.1009529
   PubMed Web of Science ®Google Scholar
• Rutigliano JA, Graham BS. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol. 2004;173(5):3408–3417. doi:10.4049/jimmunol.173.5.3408
   PubMed Web of Science ®Google Scholar
• Ostler T, Davidson W, Ehl S. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur J Immunol. 2002;32(8):2117–2123. doi:10.1002/1521-4141(200208)32:8
   PubMed Web of Science ®Google Scholar
• Kitcharoensakkul M, Bacharier LB, Yin-Declue H, et al. Impaired tumor necrosis factor-α secretion by CD4 T cells during respiratory syncytial virus bronchiolitis associated with recurrent wheeze. Immun Inflamm Dis. 2020;8(1):30–39. doi:10.1002/iid3.281
   PubMed Web of Science ®Google Scholar
• Roumanes D, Falsey AR, Quataert S, et al. T-cell responses in adults during natural respiratory syncytial virus infection. J Infect Dis. 2018;218(3):418–428. doi:10.1093/infdis/jiy016
   PubMed Web of Science ®Google Scholar
• Legardinier S, Klett D, Poirier JC, Combarnous Y, Cahoreau C. Mammalian-like nonsialyl complex-type N-glycosylation of equine gonadotropins in Mimic insect cells. Glycobiology. 2005;15(8):776–790. doi:10.1093/glycob/cwi060
   PubMed Web of Science ®Google Scholar
• Toth AM, Kuo CW, Khoo KH, Jarvis DL. A new insect cell glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency. J Biotechnol. 2014;182–183:19–29. doi:10.1016/j.jbiotec.2014.04.011
   PubMed Web of Science ®Google Scholar
• Chavez-Pena C, Kamen AA. RNA interference technology to improve the baculovirus-insect cell expression system. Biotechnol Adv. 2018;36(2):443–451. doi:10.1016/j.biotechadv.2018.01.008
   PubMed Web of Science ®Google Scholar